U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06392867) titled 'Intermittent Theta-burst Stimulation for Major Depression: an Intensity-response Study' on April 23.
Brief Summary: The United States Food and Drug Administration (FDA) approved intermittent theta-burst stimulation (iTBS) in 2018 as a form of repetitive transcranial magnetic stimulation (rTMS). Hospitals worldwide use it to treat major depressive disorder (MDD). It is safe, effective, even for depressed patients unable to respond to standard pharmacological treatment and is more efficient than standard rTMS. In accordance with the approved treatment protocol, patients experience considerable sensory discomfort at a stimulation intensi...